sulfotransferase family 1A member 2Genealiases: HAST4 · P-PST · P-PST 2 · ST1A2 · STP2 · TSPST2
Q-omics provides the consensus-scored SULT1A2 profile across patient tissues and cancer cell-line models. SULT1A2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SULT1A2 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, SULT1A2 RNA expression shows 13,906 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, COAD, and TGCT as cancer lineages where SULT1A2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SULT1A2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SULT1A2 survival associations across molecular data types. SULT1A2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SULT1A2 RNA expression–survival associations across cancer types. High SULT1A2 expression shows unfavorable associations in UCS, KIRC and CHOL, but favorable associations in MESO, OV and SKCM. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for SULT1A2 RNA expression.
This table summarizes SULT1A2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SULT1A2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SULT1A2 shows lower tumor expression in COAD, LUSC, THCA, LUAD, READ and LIHC. The COAD box plot shows higher SULT1A2 RNA expression in normal versus tumor tissue (log2 FC = −3.382, t-test p < 0.001).
This table shows molecular features associated with SULT1A2 in patient tissues and cancer cell lines. In patient samples, SULT1A2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SULT1A2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
